Todd Michael Pollack, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vietnam | 13 | 2024 | 415 | 1.250 |
Why?
|
Viral Load | 3 | 2019 | 3398 | 0.920 |
Why?
|
HIV Infections | 11 | 2024 | 17591 | 0.890 |
Why?
|
Health Personnel | 6 | 2024 | 3383 | 0.540 |
Why?
|
HIV Protease Inhibitors | 2 | 2009 | 432 | 0.520 |
Why?
|
Telemedicine | 2 | 2022 | 3110 | 0.440 |
Why?
|
Qualitative Research | 1 | 2024 | 3143 | 0.430 |
Why?
|
HIV | 1 | 2019 | 1597 | 0.380 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1798 | 0.340 |
Why?
|
Dibenzothiazepines | 1 | 2009 | 102 | 0.330 |
Why?
|
Anti-HIV Agents | 3 | 2024 | 4576 | 0.290 |
Why?
|
Ritonavir | 1 | 2009 | 332 | 0.290 |
Why?
|
CD4 Lymphocyte Count | 3 | 2019 | 2598 | 0.260 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2007 | 622 | 0.230 |
Why?
|
Oligopeptides | 1 | 2009 | 1194 | 0.230 |
Why?
|
HIV-1 | 2 | 2018 | 6962 | 0.210 |
Why?
|
Anti-Retroviral Agents | 3 | 2022 | 1795 | 0.200 |
Why?
|
Capacity Building | 2 | 2015 | 265 | 0.190 |
Why?
|
Injections | 1 | 2024 | 841 | 0.190 |
Why?
|
Delayed-Action Preparations | 1 | 2024 | 969 | 0.180 |
Why?
|
Smoking | 1 | 2017 | 9094 | 0.170 |
Why?
|
Developing Countries | 2 | 2022 | 2911 | 0.160 |
Why?
|
Pyridines | 1 | 2009 | 2895 | 0.140 |
Why?
|
Health Facilities | 1 | 2022 | 577 | 0.140 |
Why?
|
Antipsychotic Agents | 1 | 2009 | 3081 | 0.130 |
Why?
|
Infection Control | 2 | 2020 | 985 | 0.130 |
Why?
|
Social Stigma | 1 | 2022 | 788 | 0.130 |
Why?
|
Patient Participation | 2 | 2020 | 1448 | 0.110 |
Why?
|
Patient-Centered Care | 1 | 2024 | 1447 | 0.110 |
Why?
|
Cytomegalovirus Retinitis | 1 | 2013 | 56 | 0.110 |
Why?
|
Public Sector | 1 | 2015 | 266 | 0.110 |
Why?
|
Program Evaluation | 2 | 2020 | 2508 | 0.110 |
Why?
|
Education, Nursing, Continuing | 1 | 2013 | 69 | 0.110 |
Why?
|
Education, Medical, Undergraduate | 1 | 2022 | 1085 | 0.110 |
Why?
|
Medication Adherence | 1 | 2024 | 2192 | 0.100 |
Why?
|
Guideline Adherence | 2 | 2020 | 2241 | 0.100 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5375 | 0.090 |
Why?
|
Cross Infection | 1 | 2020 | 1425 | 0.090 |
Why?
|
Treatment Failure | 1 | 2017 | 2664 | 0.090 |
Why?
|
Humans | 18 | 2024 | 768970 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2013 | 664 | 0.090 |
Why?
|
Cytomegalovirus | 1 | 2013 | 753 | 0.080 |
Why?
|
Substance Abuse, Intravenous | 1 | 2013 | 530 | 0.080 |
Why?
|
Adult | 7 | 2024 | 223851 | 0.080 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2017 | 1903 | 0.080 |
Why?
|
Myocardial Infarction | 1 | 2007 | 11521 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5522 | 0.070 |
Why?
|
Middle Aged | 6 | 2024 | 223737 | 0.060 |
Why?
|
Male | 8 | 2024 | 365203 | 0.060 |
Why?
|
Drug Interactions | 1 | 2009 | 1418 | 0.060 |
Why?
|
Female | 8 | 2024 | 397515 | 0.060 |
Why?
|
Philippines | 1 | 2024 | 95 | 0.060 |
Why?
|
Young Adult | 3 | 2024 | 60131 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26395 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 14752 | 0.050 |
Why?
|
Adolescent | 3 | 2020 | 89244 | 0.050 |
Why?
|
Quality Improvement | 1 | 2015 | 3860 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13674 | 0.040 |
Why?
|
Prospective Studies | 3 | 2020 | 54962 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 6320 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15951 | 0.040 |
Why?
|
Hepatitis B | 1 | 2024 | 711 | 0.040 |
Why?
|
Aged | 3 | 2024 | 171786 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2024 | 2744 | 0.030 |
Why?
|
Ecosystem | 1 | 2020 | 494 | 0.030 |
Why?
|
Risk | 1 | 2007 | 9621 | 0.030 |
Why?
|
Primary Health Care | 2 | 2022 | 4748 | 0.030 |
Why?
|
Medical Assistance | 1 | 2015 | 108 | 0.030 |
Why?
|
Nuclear Family | 1 | 2015 | 311 | 0.030 |
Why?
|
Hepatitis C | 1 | 2024 | 1595 | 0.030 |
Why?
|
Models, Nursing | 1 | 2013 | 47 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12095 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 951 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 4056 | 0.020 |
Why?
|
Models, Educational | 1 | 2013 | 375 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18435 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2020 | 1876 | 0.020 |
Why?
|
Risk Factors | 1 | 2017 | 74976 | 0.020 |
Why?
|
Family | 1 | 2020 | 3208 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1300 | 0.020 |
Why?
|
Educational Measurement | 1 | 2013 | 1260 | 0.020 |
Why?
|
Vision Disorders | 1 | 2013 | 1093 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3800 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13318 | 0.020 |
Why?
|
Visual Acuity | 1 | 2013 | 2714 | 0.010 |
Why?
|
Nurses | 1 | 2013 | 2501 | 0.010 |
Why?
|
Child | 2 | 2020 | 80960 | 0.010 |
Why?
|
Pilot Projects | 1 | 2013 | 8748 | 0.010 |
Why?
|
Curriculum | 1 | 2013 | 3782 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26428 | 0.010 |
Why?
|
Clinical Competence | 1 | 2015 | 4860 | 0.010 |
Why?
|
Infant | 1 | 2020 | 36556 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15471 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 42683 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15879 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2024 | 81903 | 0.010 |
Why?
|